Barclays Raises AnaptysBio Price Target to $79

Analysts see potential 41% upside for the biotech company's stock.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Barclays analysts have raised their price target for AnaptysBio (NASDAQ:ANAB) from $78 to $79, maintaining an "overweight" rating on the stock. The new target price represents a potential upside of 41.07% from the stock's previous close. Several other research firms have also issued positive ratings and price targets for AnaptysBio in recent months.

Why it matters

The increased price target from Barclays suggests analysts see strong growth potential for AnaptysBio, a clinical-stage biotech company focused on developing therapeutic antibodies for immunology and inflammation. The company's pipeline includes multiple programs in late-stage clinical trials, which could drive future value if successful.

The details

Barclays cited AnaptysBio's progress in its clinical programs as the reason for the price target increase. The company is developing treatments for various dermatological and inflammatory disorders. In addition to Barclays, several other research firms have issued positive ratings and price targets for AnaptysBio in recent months, including Guggenheim, Wells Fargo, and UBS.

  • Barclays issued the updated price target and rating on Wednesday, March 4, 2026.

The players

Barclays

A multinational investment bank and financial services company that provides research coverage on AnaptysBio.

AnaptysBio

A clinical-stage biotechnology company focused on developing therapeutic antibodies for immunology and inflammation.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The increased price target from Barclays reflects analysts' confidence in AnaptysBio's ability to advance its pipeline of immunology and inflammation treatments, which could drive significant value for the company and its shareholders if successful.